Drugs / Lanabecestat
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 116 trials | ||||||
| Phase 1 | NCT03499041 | Jun → Dec 2018 | — | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 1 | NCT03545087 | Jun 2018 → Jan 2019 | impaired renal function disease | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 1 | NCT03506399 | Jun → Oct 2018 | — | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 1 | NCT03222427 | Jan → Feb 2018 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03019549 | Jan → May 2017 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02663128 | Jan → Mar 2016 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02568397 | Oct 2015 → Jan 2016 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02540668 | Sep 2015 → Jan 2016 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02406261 | Apr → Aug 2015 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02126514 | May 2014 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02039180 | Feb → Mar 2014 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02040987 | Jan → May 2014 | Alzheimer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02005211 | Dec 2013 → Jul 2014 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02010970 | Dec 2013 → Feb 2014 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01795339 | Mar 2013 → Mar 2014 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01739647 | Dec 2012 → May 2013 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT02245737 | Sep 2014 → Oct 2018 | Alzheimer disease | AstraZeneca | Terminated | Missed primary |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT02972658 | Mar 2017 → Oct 2018 | Alzheimer disease | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT02783573 | Jul 2016 → Sep 2018 | Alzheimer disease | AstraZeneca | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2018-06-12 | AstraZeneca | Results Update on Phase III clinical trials of lanabecestat for Alzheimer’s disease astrazeneca.com ↗
The decision is based on recommendations by an independent data monitoring committee (IDMC), which concluded that both the AMARANTH trial, in early Alzheimer’s disease, and the DAYBREAK-ALZ trial, in mild Alzheimer’s disease dementia, were not likely to meet their primary endpoints upon completion and therefore should be stopped for futility. |
| 2018-06-12 | Eli Lilly and Company | Results Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease lilly.com ↗
Eli Lilly and Company (NYSE: LLY) and AstraZeneca are discontinuing the global Phase 3 clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer's disease. |
| 2016-08-22 | AstraZeneca | Regulatory AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease astrazeneca.com ↗ |
| 2016-08-22 | Eli Lilly and Company | Regulatory Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293, an Investigational Treatment for Early Alzheimer's Disease lilly.com ↗ |
| 2016-04-08 | AstraZeneca | Results AstraZeneca and Eli Lilly and Company announce continuation of pivotal clinical trial for people with early Alzheimer’s disease astrazeneca.com ↗
The AMARANTH independent data monitoring committee recommended the study continue without modification after a scheduled interim safety analysis was conducted. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-06-12 | AstraZeneca | Update on Phase III clinical trials of lanabecestat for Alzheimer’s disease astrazeneca.com ↗ |
| 2018-06-12 | Eli Lilly and Company | Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease lilly.com ↗ |
| 2016-08-22 | AstraZeneca | AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease astrazeneca.com ↗ |
| 2016-08-22 | Eli Lilly and Company | Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293, an Investigational Treatment for Early Alzheimer's Disease lilly.com ↗ |
| 2016-04-08 | AstraZeneca | AstraZeneca and Eli Lilly and Company announce continuation of pivotal clinical trial for people with early Alzheimer’s disease astrazeneca.com ↗ |
| 2014-09-16 | AstraZeneca | AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease astrazeneca.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lanabecestat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02540668 ↗ |
| Known as | AZD3293 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02040987 ↗ |
| Known as | LANABECESTAT (AZD3293) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989948 ↗ |
| Known as | LY3314814 | “AZD3293 (also known as LY3314814) is a novel, potent, non-selective BACE1/BACE2 inhibitor currently in Phase 3 clinical development for the treatment of Alzheimer's disease.” PMID 29199322 ↗ 2016 |
| Action | Inhibit | “non-selective BACE1/BACE2 inhibitor” PMID 29199322 ↗ 2016 |
| Modality | Small molecule | — CHEMBL3989948 ↗ |
| Route | Oral | “Oral solution” NCT01795339 ↗ |
| Target | BACE1 | “non-selective BACE1/BACE2 inhibitor” PMID 29199322 ↗ 2016 |
| Target | BACE2 | “non-selective BACE1/BACE2 inhibitor” PMID 29199322 ↗ 2016 |